Status and phase
Conditions
Treatments
About
The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis vulgaris.
Full description
LEO 90105 ointment contains both calcipotriol and betamethasone dipropionate. It has been approved for the treatment of psoriasis in more than 60 centres, including most European countries, the US, China, Korea and Taiwan. This trial will investigate its safety and efficacy in the treatment of Japanese subjects with psoriasis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
psoriasis affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs).
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
676 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal